Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Garadacimab→

Garadacimab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not available
Molecular formula
C6382H9846N1686O1994S42
Molecular weight
~143700 g/mol
Drug class
Activated factor XII (FXIIa) inhibitorfully human monoclonal antibody
Mechanism of action
Binds the catalytic domain of activated factor XII (FXIIa and βFXIIa) and inhibits its activity. This reduces activation of prekallikrein to kallikrein and subsequent bradykinin generation in the contact activation/kallikrein–kinin pathway.
Indications / reported uses
  • Routine prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and paediatric patients aged 12 years and older under the US ANDEMBRY indication (approved 16 June 2025); not for treatment of an acute HAE attack

Sources: US FDA prescribing information — ANDEMBRY (garadacimab-gxii) · FDA Orphan Drug database — Garadacimab marketing approval and indication · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Activated factor XII (FXIIa) inhibitor; fully human monoclonal antibody

Mechanism of action

Binds the catalytic domain of activated factor XII (FXIIa and βFXIIa) and inhibits its activity. This reduces activation of prekallikrein to kallikrein and subsequent bradykinin generation in the contact activation/kallikrein–kinin pathway.

General use cases

  • Routine prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and paediatric patients aged 12 years and older under the US ANDEMBRY indication (approved 16 June 2025); not for treatment of an acute HAE attack

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Garadacimab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Garadacimab Permitted Daily Exposure (PDE) report (the Garadacimab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Garadacimab Occupational Exposure Limit (OEL) report (the Garadacimab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.